Sinovac Biotech Ltd (SVA): R&D Expense
$216.18M
Year ended 2025-12-31
-23.3%
3-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $216.18M | -20.1% | 2026-06-05, From 2025-01-01 |
| 2024-12-31 | $270.66M | -22.7% | 2026-06-05, From 2024-01-01 |
| 2023-12-31 | $350.19M | -26.8% | 2026-06-05, From 2023-01-01 |
| 2022-12-31 | $478.69M | +213.5% | 2026-04-30, From 2022-01-01 |
| 2021-12-31 | $152.70M | n/c | 2026-04-30, From 2021-01-01 |
| 2020-12-31 | $48.76M | +101.0% | 2023-05-01, From 2020-01-01 |
| 2019-12-31 | $24.25M | +10.7% | 2022-04-29, From 2019-01-01 |
| 2018-12-31 | $21.91M | +6.9% | 2021-04-22, From 2018-01-01 |
| 2017-12-31 | $20.49M | +62.0% | 2020-04-30, From 2017-01-01 |
| 2016-12-31 | $12.65M | +33.3% | 2019-04-29, From 2016-01-01 |
| 2015-12-31 | $9.49M | -13.2% | 2018-05-11, From 2015-01-01 |
| 2014-12-31 | $10.93M | +34.5% | 2017-11-22, From 2014-01-01 |
| 2013-12-31 | $8.13M | n/c | 2016-04-25, From 2013-01-01 |
| 2012-12-31 | $17.04M | +89.2% | 2015-04-29, From 2012-01-01 |
| 2011-12-31 | $9.01M | +5.9% | 2014-04-16, From 2011-01-01 |
| 2010-12-31 | $8.51M | +93.1% | 2013-05-23, From 2010-01-01 |
| 2009-12-31 | $4.41M | n/a | 2012-04-12, From 2009-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Sinovac Biotech Ltd (SVA) | 2025-12-31 | $216.18M | -20.1% |
| Arcutis Biotherapeutics, Inc. (ARQT) | 2025-12-31 | $77.05M | +0.8% |
| Ardelyx, Inc. (ARDX) | 2025-12-31 | $71.53M | +36.7% |
| Innoviva, Inc. (INVA) | 2025-12-31 | $30.60M | +124.1% |
| MannKind Corp (MNKD) | 2025-12-31 | $66.35M | +44.6% |
| Zai Lab Ltd (ZLAB) | 2025-12-31 | $220.90M | -5.8% |
| CorMedix Inc. (CRMD) | 2025-12-31 | $19.33M | +390.4% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $1.90M | +11.8% |
| Travere Therapeutics, Inc. (TVTX) | 2025-12-31 | $206.01M | -5.3% |
Compare SVA, ARQT, ARDX, INVA side by side · Screen every company in Pharmaceutical Preparations ↗